Pharmanovia announced on September 18 the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from global healthcare company, Sanofi. According to data captured in the LevinPro HC database, this transaction is the 75th Pharmaceutical acquisition of 2023.
Sanofi is selling a portfolio of CNS brands, including Frisium®, Sentil®, Urbanyl®, Urbanil®, Urbanol®, Urbadan®, Noiafren®, Castilium®, Gardenal®, Tercian® and Stemetil®. The brands span four therapy areas of ongoing unmet need associated with CNS disorders – psycholeptic, anxiolytic, anti-epileptic and anti-psychotic.
Pharmanovia (formerly known as Atnahs Pharma UK Limited) is a specialty pharmaceutical company, commercializing and marketing branded prescription medicines around the world.
Headquartered in Paris, France, Sanofi is a global pharmaceutical company focused on preventing illness with vaccines and providing treatments to fight pain.
Pharmanovia fits with Pharmanovia’s existing neurology portfolio and commercial capabilities. The acquisition will deepen CNS footprint in Brazil, South Africa, France and Italy. Financial terms of the deal were not disclosed.
